Seeking Alpha

Ampio Pharmaceuticals reports additional Ampion data

  • Ampio Pharmaceuticals (AMPE) is out with more data from SPRING (see initial read-out from August) which shows Ampion achieved "significant results [on] secondary end points."
  • Reduction in pain versus saline was significant across the entire 12-week period.
  • A single injection produced "a clinically and statistically significant reduction in pain, with an estimated difference from control at the study endpoint of -0.25 on the WOMAC A scale." (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector